Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914162 | 1.00 | RXFP1 (0.50) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL23259553 | 1.00 | RXFP1 (0.50) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL7540602 | 0.85 | KDM4E (0.55) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL30914161 | 0.82 | RXFP1 (0.52) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL23259552 | 0.82 | RXFP1 (0.52) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL29702265 | 0.80 | RXFP1 (0.55) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL222446 | 0.80 | RXFP1 (0.55) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL29992092 | 0.80 | RXFP1 (0.59) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL29663621 | 0.80 | RXFP1 (0.55) | RXFP1LMNAPOLBRAB9AKMT2A | |
| SCHEMBL15368377 | 0.80 | RXFP1 (0.59) | RXFP1LMNAPOLBRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634160-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Certa Therapeutics Pty Ltd (AU) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024124279-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CERTA THERAPEUTICS PTY LTD (AU) | 2024-06-20 | — | — | WO | disclosed |
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | TUBB, TUBB1, TUBA1C | RXFP1 4761/4885LMNA 1503/4885POLB 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.